Market Overview

Edison Investment Research Comments on Vertex Pharmaceuticals' VX-661 Data


In a report published Friday, Edison Investment Research analyst Jason Zhang commented on Vertex Pharmaceuticals (NASDAQ: VRTX).

In the report, Zhang noted, “Vertex's remarkable c $7.2bn (62%) increase in market capitalisation last week, on the back of VX-661 Phase IIa top-line data in cystic fibrosis (CF) patients with two copies of F580del mutations, poses a difficult question for investors. While the valuation reflects the market's confidence in the strength of its potential franchise in CF – possibly worth up to $10bn in peak sales – it also assumes a high probability of success. Vertex is now the undisputed leader in CF with one approved (Kalydeco, ivacaftor) drug and three clinical candidates (VX-809, -661 and -983) in the pipeline, but Edison cautions that the risk is now asymmetric to the downside.”

Vertex Pharmaceuticals closed on Thursday at $80.32.

Latest Ratings for VRTX

Nov 2020BernsteinInitiates Coverage OnOutperform
Oct 2020Credit SuisseMaintainsOutperform
Oct 2020SVB LeerinkMaintainsMarket Perform

View More Analyst Ratings for VRTX
View the Latest Analyst Ratings


Related Articles (VRTX)

View Comments and Join the Discussion!

Posted-In: Edison Investment ResearchAnalyst Color Analyst Ratings

Latest Ratings

HYMCBMO CapitalInitiates Coverage On
DEMorgan StanleyMaintains335.0
SBNYRaymond JamesMaintains138.0
CORTHC Wainwright & Co.Maintains32.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at